[go: up one dir, main page]

NO901710D0 - Syre-resistent fgf-sammensetning og fremgangsmaate for behandling av saardannende sykdommer i mave-tarm kanalen - Google Patents

Syre-resistent fgf-sammensetning og fremgangsmaate for behandling av saardannende sykdommer i mave-tarm kanalen

Info

Publication number
NO901710D0
NO901710D0 NO901710A NO901710A NO901710D0 NO 901710 D0 NO901710 D0 NO 901710D0 NO 901710 A NO901710 A NO 901710A NO 901710 A NO901710 A NO 901710A NO 901710 D0 NO901710 D0 NO 901710D0
Authority
NO
Norway
Prior art keywords
acid
resistant
treatment
diseases
mave
Prior art date
Application number
NO901710A
Other languages
English (en)
Norwegian (no)
Other versions
NO901710L (no
Inventor
Moses J Folkman
Kato Koichi
Original Assignee
Childrens Medical Center
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Takeda Chemical Industries Ltd filed Critical Childrens Medical Center
Publication of NO901710L publication Critical patent/NO901710L/no
Publication of NO901710D0 publication Critical patent/NO901710D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO901710A 1988-08-19 1990-04-18 Syre-resistent fgf-sammensetning og fremgangsmaate for behandling av saardannende sykdommer i mave-tarm kanalen NO901710D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23496688A 1988-08-19 1988-08-19
US07/382,263 US5175147A (en) 1988-08-19 1989-07-20 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
PCT/US1989/003467 WO1990001941A1 (fr) 1988-08-19 1989-08-11 Composition de facteurs de croissance des fibroblastes resistante aux acides et procede de traitement de maladies ulceratives de l'appareil gastro-intestinal

Publications (2)

Publication Number Publication Date
NO901710L NO901710L (no) 1990-04-18
NO901710D0 true NO901710D0 (no) 1990-04-18

Family

ID=26928432

Family Applications (1)

Application Number Title Priority Date Filing Date
NO901710A NO901710D0 (no) 1988-08-19 1990-04-18 Syre-resistent fgf-sammensetning og fremgangsmaate for behandling av saardannende sykdommer i mave-tarm kanalen

Country Status (16)

Country Link
US (2) US5175147A (fr)
EP (1) EP0360006B1 (fr)
JP (1) JP2501480B2 (fr)
KR (1) KR920700040A (fr)
CN (1) CN1040741A (fr)
AT (1) ATE91628T1 (fr)
CA (1) CA1330757C (fr)
DE (1) DE68907679T2 (fr)
DK (1) DK93890A (fr)
ES (1) ES2058423T3 (fr)
FI (2) FI901949A7 (fr)
HU (1) HU207227B (fr)
IE (1) IE63046B1 (fr)
IL (1) IL91322A (fr)
NO (1) NO901710D0 (fr)
WO (1) WO1990001941A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
JPH0343088A (ja) * 1989-09-29 1991-02-25 Takeda Chem Ind Ltd ａＦＧＦ蛋白質の製造法
CA2020720A1 (fr) * 1989-07-13 1991-01-14 Shigeko Yamazaki Methode de purification d'un facteur de croissance de fibroblaste acide recombinant ayant une action therapeutique
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
ES2123004T3 (es) * 1991-04-12 1999-01-01 Creative Biomolecules Inc Uso de factor de crecimiento derivado de plaquetas en la preparacion de un medicamento para el tratamiento de ulceras gastrointestinales.
NO921495L (no) * 1991-04-16 1992-10-19 Seikagaku Kogyo Co Ltd Oligosakkarid og fremgangsmaate for dets fremstilling
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
JPH07507926A (ja) * 1992-06-16 1995-09-07 ホイツテイアー・インステイテユート・フオー・ダイアビテイーズ・アンド・エンドクリノロジー サポリン含有タンパク質の組換え産生
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
FR2718023B1 (fr) * 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5531880A (en) * 1994-09-13 1996-07-02 Microelectronics And Computer Technology Corporation Method for producing thin, uniform powder phosphor for display screens
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
AU2001284914B2 (en) * 2000-08-15 2006-02-09 New Technologies Holdings Pte Ltd Phage-dependent superproduction of biologically active protein and peptides
WO2002017956A2 (fr) * 2000-08-31 2002-03-07 Chiron Corporation Formulations stabilisees a base de fgf contenant des agents reducteurs
WO2002064093A2 (fr) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Compositions pharmaceutiques stabilisees, compositions d'hormone de thyroide et technique de preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
CA3091215A1 (fr) * 2018-02-13 2019-08-22 University Of Florida Research Foundation Analogues du facteur de croissance des fibroblastes et leurs utilisations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
EP0105014B1 (fr) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Rétablissement de tissu chez les animaux
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
JPS6028999A (ja) * 1983-06-30 1985-02-14 Maruho Kk 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
CA1207239A (fr) * 1984-08-10 1986-07-08 Upendra K. Banik Compose gastro-intestinal
JPS6172947A (ja) * 1984-09-18 1986-04-15 Takasago Thermal Eng Co Ltd クリ−ンル−ムの形成法およびこの方法に使用する空気調和設備ユニツト
EP0593065B1 (fr) * 1985-09-12 2002-08-21 Scios Inc. Facteurs de croissance de fibroblastes recombinants
WO1989000198A1 (fr) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Facteurs de croissance de fibroblastes recombinants
IL81839A0 (en) * 1986-03-14 1987-10-20 Takeda Chemical Industries Ltd Polypeptide,dna and its use
CA1294546C (fr) * 1986-04-23 1992-01-21 John S. Sundsmo Composition cicatrisante contenant du collagene
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
CA1323317C (fr) * 1987-01-16 1993-10-19 Allen R. Banks Production de facteur de croissance de fibroblastes
FI893530A7 (fi) * 1987-11-24 1989-07-21 Amgen Inc Fibroblasti-kasvutekijän analogeja
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
JPH0240399A (ja) * 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物

Also Published As

Publication number Publication date
WO1990001941A1 (fr) 1990-03-08
FI943028L (fi) 1994-06-22
AU630111B2 (en) 1992-10-22
IE63046B1 (en) 1995-03-22
HU895785D0 (en) 1990-12-28
IL91322A0 (en) 1990-03-19
FI901949A0 (fi) 1990-04-18
FI943028A7 (fi) 1994-06-22
HU207227B (en) 1993-03-29
NO901710L (no) 1990-04-18
JP2501480B2 (ja) 1996-05-29
HUT55638A (en) 1991-06-28
DK93890D0 (da) 1990-04-17
IL91322A (en) 1994-12-29
ATE91628T1 (de) 1993-08-15
IE892664L (en) 1990-02-19
US5401721A (en) 1995-03-28
CA1330757C (fr) 1994-07-19
DE68907679T2 (de) 1994-01-27
JPH03505736A (ja) 1991-12-12
ES2058423T3 (es) 1994-11-01
EP0360006B1 (fr) 1993-07-21
AU4218989A (en) 1990-03-23
CN1040741A (zh) 1990-03-28
DE68907679D1 (de) 1993-08-26
DK93890A (da) 1990-04-17
US5175147A (en) 1992-12-29
KR920700040A (ko) 1992-02-19
EP0360006A2 (fr) 1990-03-28
FI901949A7 (fi) 1990-04-18
FI943028A0 (fi) 1994-06-22
EP0360006A3 (en) 1990-04-04

Similar Documents

Publication Publication Date Title
NO901710D0 (no) Syre-resistent fgf-sammensetning og fremgangsmaate for behandling av saardannende sykdommer i mave-tarm kanalen
NO894296L (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
FI900052A7 (fi) Koostumuksia ja hoitomenetelmiä peräpukamia ja muita varten
EP0493362A3 (en) Compositions and kits for the treatment of oral diseases
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE69021386D1 (de) Verfahren und zusammensetzungen zur heilung von geschwüren.
NZ223045A (en) Fluticasone propionate compositions with an enteric coating
DE69019886D1 (de) Katheter und Instrumentarium zur extrakorporalen Zirkulation.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
NO830527L (no) Analogifremgangsmaate for fremstilling av 2,3-diaryl-5-halogenthiofener
AU2158688A (en) Use of bezafibrate for treating diabetes
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
NO865302L (no) Fremgangsmaate for fremstilling av immunoforsterkere og beslektede forbindelser.
GR3005231T3 (fr)
NO884635D0 (no) Fremgangsmaate for behandling av most.
EP0293925A3 (en) Compound active in cardiovasular therapy
EP0200214A3 (en) Treatment of parasitic diseases
NZ333652A (en) Inhibition of human rotavirus infection using kappa-casein
ATE47400T1 (de) Gel zur verhuetung der adhaesion von koerpergeweben und dessen herstellung.
IL66699A0 (en) Method for diagnosing and for the therapeutic treatment of tumors and/or infections diseases of different types with alkaloidcompounds
PH25193A (en) Method and composition for the prophylaxis and treatment of retroviral infection
NO893324D0 (no) Behandling av maligne tumorer med 8-kloradenosin-3',5'-cyklisk fosfat, 8-aminoadenosin-3',5'-cyklisk fosfat og fremstilling derav.
NO872634D0 (no) Fremgangsmaate og anlegg for behandling av amoniakk.